Boryung Corporation (003850.KS)
KRW 10260.0
(-3.39%)
KRW 10260.0
(-3.39%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 922.36 Billion KRW | 3.36% |
| 2022 | 892.38 Billion KRW | 7.69% |
| 2021 | 828.64 Billion KRW | 27.88% |
| 2020 | 647.99 Billion KRW | 27.65% |
| 2019 | 507.62 Billion KRW | 12.8% |
| 2018 | 450.01 Billion KRW | 11.8% |
| 2017 | 402.51 Billion KRW | 1.16% |
| 2016 | 397.9 Billion KRW | 20.24% |
| 2015 | 330.92 Billion KRW | 17.18% |
| 2014 | 282.4 Billion KRW | 5.55% |
| 2013 | 267.55 Billion KRW | -1.99% |
| 2012 | 273 Billion KRW | 4.05% |
| 2011 | 262.38 Billion KRW | 23.11% |
| 2010 | 213.12 Billion KRW | 20.56% |
| 2009 | 176.78 Billion KRW | 6.36% |
| 2008 | 166.2 Billion KRW | 2.54% |
| 2007 | 162.09 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1029.65 Billion KRW | 2.82% |
| 2024 Q1 | 1001.42 Billion KRW | 8.57% |
| 2023 Q3 | 937.6 Billion KRW | 3.77% |
| 2023 Q2 | 903.57 Billion KRW | -5.14% |
| 2023 FY | 922.36 Billion KRW | 3.36% |
| 2023 Q1 | 952.57 Billion KRW | 6.74% |
| 2023 Q4 | 922.36 Billion KRW | -1.63% |
| 2022 Q2 | 866.54 Billion KRW | 1.07% |
| 2022 FY | 892.38 Billion KRW | 7.69% |
| 2022 Q4 | 892.38 Billion KRW | -2.13% |
| 2022 Q3 | 911.77 Billion KRW | 5.22% |
| 2022 Q1 | 857.38 Billion KRW | 3.47% |
| 2021 Q2 | 682.13 Billion KRW | 1.72% |
| 2021 Q3 | 807.73 Billion KRW | 18.41% |
| 2021 Q4 | 828.64 Billion KRW | 2.59% |
| 2021 FY | 828.64 Billion KRW | 27.88% |
| 2021 Q1 | 670.62 Billion KRW | 3.49% |
| 2020 Q3 | 683.74 Billion KRW | 8.83% |
| 2020 FY | 647.99 Billion KRW | 27.65% |
| 2020 Q4 | 647.99 Billion KRW | -5.23% |
| 2020 Q1 | 494.44 Billion KRW | -2.6% |
| 2020 Q2 | 628.28 Billion KRW | 27.07% |
| 2019 FY | 507.62 Billion KRW | 12.8% |
| 2019 Q4 | 507.62 Billion KRW | -0.05% |
| 2019 Q3 | 507.86 Billion KRW | 3.53% |
| 2019 Q2 | 490.53 Billion KRW | 1.84% |
| 2019 Q1 | 481.65 Billion KRW | 7.03% |
| 2018 Q4 | 450.01 Billion KRW | -0.75% |
| 2018 Q2 | 410.12 Billion KRW | 1.06% |
| 2018 FY | 450.01 Billion KRW | 11.8% |
| 2018 Q1 | 405.83 Billion KRW | 0.82% |
| 2018 Q3 | 453.42 Billion KRW | 10.56% |
| 2017 Q1 | 421.74 Billion KRW | 5.99% |
| 2017 Q2 | 396.82 Billion KRW | -5.91% |
| 2017 Q4 | 402.51 Billion KRW | -6.1% |
| 2017 Q3 | 428.64 Billion KRW | 8.02% |
| 2017 FY | 402.51 Billion KRW | 1.16% |
| 2016 Q4 | 397.9 Billion KRW | 0.0% |
| 2016 FY | 397.9 Billion KRW | 20.24% |
| 2015 Q2 | 302.01 Billion KRW | 3.55% |
| 2015 FY | 330.92 Billion KRW | 17.18% |
| 2015 Q4 | 330.92 Billion KRW | 0.63% |
| 2015 Q3 | 328.86 Billion KRW | 8.89% |
| 2015 Q1 | 291.64 Billion KRW | 3.27% |
| 2014 Q3 | 291.21 Billion KRW | 7.19% |
| 2014 Q4 | 282.4 Billion KRW | -3.02% |
| 2014 FY | 282.4 Billion KRW | 5.55% |
| 2014 Q1 | 271.21 Billion KRW | 1.37% |
| 2014 Q2 | 271.67 Billion KRW | 0.17% |
| 2013 Q3 | 280.67 Billion KRW | 4.71% |
| 2013 Q4 | 267.55 Billion KRW | -4.67% |
| 2013 FY | 267.55 Billion KRW | -1.99% |
| 2013 Q1 | 267.48 Billion KRW | -2.02% |
| 2013 Q2 | 268.03 Billion KRW | 0.21% |
| 2012 Q2 | 268.86 Billion KRW | -0.89% |
| 2012 Q1 | 271.27 Billion KRW | 3.39% |
| 2012 FY | 273 Billion KRW | 4.05% |
| 2012 Q4 | 273 Billion KRW | -3.23% |
| 2012 Q3 | 282.12 Billion KRW | 4.93% |
| 2011 Q3 | 268.55 Billion KRW | 6.73% |
| 2011 FY | 262.38 Billion KRW | 23.11% |
| 2011 Q1 | 250.04 Billion KRW | 17.32% |
| 2011 Q4 | 262.38 Billion KRW | -2.3% |
| 2011 Q2 | 251.62 Billion KRW | 0.63% |
| 2010 Q1 | 201.39 Billion KRW | 13.92% |
| 2010 FY | 213.12 Billion KRW | 20.56% |
| 2010 Q4 | 213.12 Billion KRW | -5.23% |
| 2010 Q3 | 224.87 Billion KRW | 5.53% |
| 2010 Q2 | 213.08 Billion KRW | 5.8% |
| 2009 Q1 | 171.01 Billion KRW | 2.89% |
| 2009 FY | 176.78 Billion KRW | 6.36% |
| 2009 Q4 | 176.78 Billion KRW | -3.48% |
| 2009 Q3 | 183.16 Billion KRW | 6.05% |
| 2009 Q2 | 172.72 Billion KRW | 1.0% |
| 2008 Q2 | 162.48 Billion KRW | -4.43% |
| 2008 Q4 | 166.2 Billion KRW | -1.51% |
| 2008 Q3 | 168.75 Billion KRW | 3.86% |
| 2008 FY | 166.2 Billion KRW | 2.54% |
| 2008 Q1 | 170 Billion KRW | 4.88% |
| 2007 FY | 162.09 Billion KRW | 0.0% |
| 2007 Q1 | 168.21 Billion KRW | 0.0% |
| 2007 Q3 | 164.52 Billion KRW | 3.61% |
| 2007 Q4 | 162.09 Billion KRW | -1.48% |
| 2007 Q2 | 158.79 Billion KRW | -5.6% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -365.337% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 52.871% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | -5.172% |
| HANDOK Inc. | 790.33 Billion KRW | -16.704% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | -440.594% |
| Yuhan Corporation | 2814.07 Billion KRW | 67.223% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | 29.87% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -886.704% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 52.749% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | -284.723% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | -96.706% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -702.24% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | -289.924% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | -164.753% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -365.337% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | -120.034% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | -84.555% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | -56.492% |
| JW Holdings Corporation | 1176.26 Billion KRW | 21.586% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | -50.895% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | 34.231% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | -42.993% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -163.469% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -498.776% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | -148.829% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | -89.27% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -365.337% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | 14.443% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 47.898% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | -42.993% |
| Yuhan Corporation | 2814.07 Billion KRW | 67.223% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | -4.814% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | -307.042% |
| Suheung Co., Ltd. | 993.73 Billion KRW | 7.183% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | -42.993% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | -119.662% |
| Korea United Pharm Inc. | 468.86 Billion KRW | -96.724% |
| CKD Bio Corp. | 293.78 Billion KRW | -213.958% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | -81.568% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | -63.258% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | -129.885% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -163.469% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 36.651% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | -108.461% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | -96.706% |
| JW Lifescience Corporation | 255.83 Billion KRW | -260.528% |